Stock Research for NVAX


Featured Broker: Ally Invest

Get the due diligence for another stock.


NVAX Stock Chart & Research Data

The NVAX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the NVAX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


NVAX Due diligence Resources & Stock Charts

The NVAX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View NVAX Detailed Price Forecast - CNN Money CNN View NVAX Detailed Summary - Google Finance
Yahoo View NVAX Detailed Summary - Yahoo! Finance Zacks View NVAX Stock Research & Analysis -

Stock Analysis

TradeIdeas View NVAX Trends & Analysis - Trade-Ideas Barrons View NVAX Major Holders - Barrons
NASDAQ View NVAX Call Transcripts - NASDAQ Seeking View NVAX Breaking News & Analysis - Seeking Alpha
Spotlight View NVAX Annual Report - OTC Report View NVAX OTC Short Report -
TradeKing View NVAX Fundamentals - TradeKing Charts View NVAX SEC Filings - Bar Chart
WSJ View Historical Prices for NVAX - The WSJ Morningstar View Performance/Total Return for NVAX - Morningstar
MarketWatch View the Analyst Estimates for NVAX - MarketWatch CNBC View the Earnings History for NVAX - CNBC
StockMarketWatch View the NVAX Earnings - StockMarketWatch MacroAxis View NVAX Buy or Sell Recommendations - MacroAxis
Bullish View the NVAX Bullish Patterns - American Bulls Short Pains View NVAX Short Pain Metrics -

Social Media Mentions

StockTwits View NVAX Stock Mentions - StockTwits PennyStocks View NVAX Stock Mentions - PennyStockTweets
Twitter View NVAX Stock Mentions - Twitter Invest Hub View NVAX Investment Forum News - Investor Hub
Yahoo View NVAX Stock Mentions - Yahoo! Message Board Seeking Alpha View NVAX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for NVAX - Insider Cow View Insider Transactions for NVAX - Insider Cow
CNBC View NVAX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for NVAX - OTC Markets
Yahoo View Insider Transactions for NVAX - Yahoo! Finance NASDAQ View Institutional Holdings for NVAX - NASDAQ

Stock Charts

FinViz View NVAX Stock Insight & Charts - StockCharts View NVAX Investment Charts -
BarChart View NVAX Stock Overview & Charts - BarChart Trading View View NVAX User Generated Charts - Trading View

Latest Financial News for NVAX

Analyzing Novavax’s Financial Performance
Posted on Thursday August 16, 2018

Novavax (NVAX) generated revenue of $10.77 million in the second quarter compared to $6.73 million in the comparable period in 2017. The increase in the company’s revenue resulted from a $2 million increase in the Bill and Melinda Gates Foundation grant revenue due to higher enrolment in Novavax’s Prepare trial and an additional $2 million from increased activities from Novavax AB. The general and administrative expenses incurred by Novavax decreased from $8.94 million in the second quarter of 2017 to $8.22 million in the second quarter of 2018.

Gauging Analysts’ Expectations for Novavax and Peers in August
Posted on Thursday August 16, 2018

Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing to market recombinant nanoparticle vaccines and adjuvants. Novavax makes use of its proprietary recombinant nanoparticle vaccine technology and saponin-based adjuvant technology to develop vaccine candidates that target different infectious diseases, such as the respiratory syncytial virus and influenza. Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation (or BMGF), which is the current source of its revenue.

5 Promising Vaccines in Development -- and the Stocks Poised to Profit From Them
Posted on Wednesday August 15, 2018

Nearly $5 billion in combined annual sales could be on the way from these top vaccines in development.

Why Novavax, Inc. Shares Are Soaring Today
Posted on Thursday August 09, 2018

The clinical-stage biotech provided good news for two key vaccines in its pipeline.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.